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Background: While the association between affective disorders and sleep and circadian disturbance is well
established, little is known about the neurobiology underpinning these relationships. In this study, we sought to
determine the relationship between a marker of circadian rhythm and neuronal integrity (N-Acetyl Aspartate, NAA),
oxidative stress (glutathione, GSH) and neuronal-glial dysfunction (Glutamate + Glutamine, Glx).
Methods: Fifty-three young adults (age range 15? 33 years, mean = 21.8, sd = 4.3) with emerging affective disorders
were recruited from a specialized tertiary referral service. Participants underwent clinical assessment and actigraphy
monitoring, from which sleep midpoint was calculated as a marker of circadian rhythm. Proton magnetic resonance
spectroscopy was performed in the anterior cingulate cortex (ACC). The metabolites NAA, GSH and Glx were
obtained, and expressed as a ratio to Creatine.
Results: Neither NAA or GSH were associated with sleep midpoint. However, higher levels of ACC Glx were
associated with later sleep midpoints (rho = 0.35, p = 0.013). This relationship appeared to be independent of age
and depression severity.
Conclusions: This study is the first to demonstrate that delayed circadian phase is related to altered glutamatergic
processes. It is aligned with animal research linking circadian rhythms with glutamatergic neurotransmission as well
as clinical studies showing changes in glutamate with sleep interventions. Further studies may seek to examine the
role of glutamate modulators for circadian misalignment.
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It is well established that affective disorders are associ-
ated with sleep-wake and circadian disturbance [1-4].
Indeed, circadian dysfunction is postulated to play a role
in the pathogenesis of mood disturbance onset, mainten-
ance and recurrence [5-12]. In younger people with
affective disorders, data on sleep-wake and circadian
change is only beginning to emerge but suggests clear
circadian misalignment early in the course of disease.
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unless otherwise stated.40% of young patients showing this profile [13]. In
addition, advancing illness is associated with lower even-
ing melatonin secretion, as well as short phase angles be-
tween melatonin onset and habitual sleep onset [14]. Both
the unipolar and bipolar subtypes show delayed sleep and
melatonin patterns, though some data indicates more pro-
nounced phase shifts in those with bipolar disorder [4,13].
Despite the recent advances in treatments specifically
focusing on the sleep-wake system [15-18], our under-
standing of the relationship between circadian change
and underlying neurobiological processes is embryonic.
Indeed, even in healthy adults or adolescents there is a
dearth of research specifically examining the inter-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Naismith et al. BMC Psychiatry 2014, 14:345 Page 2 of 7
http://www.biomedcentral.com/1471-244X/14/345relationships between such factors. Understanding these
relationships early in the course of affective disorders is
relevant not only to further our scientific understanding
of sleep-wake and circadian change but also to inform
targeted intervention approaches [15]. Using proton
magnetic resonance spectroscopy (1H-MRS) we have
previously reported that within the anterior cingulate
cortex (ACC, a key region implicated in affective disor-
ders), the neurometabolites N-Acetyl Aspartate (NAA; a
neuronal integrity marker), glutamate (an excitatory
neurotransmitter) and glutathione (GSH; a marker of
oxidative stress) are likely to differ markedly across pa-
tient clusters despite their similar levels of current symp-
toms and functional impairments [17]. These findings
are aligned with studies showing altered levels of these
neurometabolites in affective disorders [19-22] and add-
itionally suggest that consideration of these markers is
warranted to better understand specific phenotypes, in-
cluding those with prominent sleep-wake change. In this
study, we sought to extend our work by examining
sleep-wake and circadian functioning in relation to in-
vivo measures of the brain neurometabolites NAA, GSH
and glutamate + glutamine (Glx). We hypothesised that
delayed sleep would be associated with decreased con-
centrations of NAA (indicative of neuronal comprom-
ise), GSH (indicative of oxidative stress), and increased
Glx (indicative of excitatory neurotransmission).
Methods
Participants
Fifty-three young adults (age range 15? 33 years, mean =
21.8, sd = 4.3) were recruited from specialised early inter-
vention services for youth mental health (Youth Mental
Health Clinic and headspace), Sydney, Australia [23].
Participants were a subset of a broader sample [17] partici-
pating in detailed neurobiological assessments. They were
specifically selected for this study if their psychiatrist con-
sidered them to have an emerging affective (unipolar or
bipolar) disorder [23] and they completed actigraphy
monitoring and a magnetic resonance imaging scan within
a one-month period. In addition to our usual exclusion
criteria [17], participants undertaking shift work or having
transmeridian travel within 60 days previous to data col-
lection were excluded. Participants with an alcohol and/or
substance dependence disorder were also excluded. All
participants or their parents gave written informed con-
sent prior to participation in the study. The study protocol




As described elsewhere [23], patients were receiving
care for their mental health disorder by a mental healthprofessional and a clinical psychiatrist (namely ES, IH)
confirmed affective disorder diagnoses. In addition, all par-
ticipants were assessed by a trained research psychologist
who recorded depression and mania symptom severity
using the 17-item Hamilton Depression Rating Scale
(HAM-D) [24]. Manic symptoms were rated for a subset
of 39 participants using the Young Mania Rating Scale
(YMRS) [25]. Twenty participants were taking antidepres-
sant medications at the time of assessment which included
nine taking selective serotonin reuptake inhibitors, seven
taking serotonin noradrenaline reuptake inhibitors, one
taking a monoamine oxidase inhibitor, one taking a no-
radrenergic and specific serotonergic antidepressant, one
taking a melatonergic antidepressant and one taking an
atypical antidepressant. In addition, 11 participants were
taking mood stabilising medications and 12 were taking
antipsychotic medications. Thirty-two patients were classi-
fied as emerging unipolar and 21 as emerging bipolar
disorder.
Sleep-wake ambulatory assessment
Participants completed sleep diary and actigraphy moni-
toring (Actiwatch-64/L/2, Philips Respironics, USA) for
14 days (mean duration = 12.2 days, sd = 3.3 days; median
duration = 13.0 days) within one month of undergoing 1H-
MRS. Actiware 5.0 software (Philips Respironics) was used
to score actigraphy using a wake threshold value of
medium sensitivity (40.0 activity counts/epoch). Based on
sleep diaries, corrections by trained technicians were ap-
plied where necessary. Rest intervals were subsequently
submitted to dual integration to define periods spent
awake and resting. For the purpose of this study, acti-
graphic measures will be defined as ? sleep'. The following
actigraphic sleep variables were obtained for descriptive
purposes: ? sleep onset? and ? sleep offset? (mean timing of
the onset/offset of the rest intervals, respectively), time in
bed (TiB: total duration of the rest intervals), total sleep
time (TST: amount of time scored as ? sleep? within the
rest episode), ?wake after sleep onset? (WASO: amount of
time scored as ? wake? within the rest episode), and sleep
efficiency (? total sleep time? /? time in bed? )*100). The pri-
mary outcome of this study was the ? sleep midpoint?, de-
fined as ? TST/2 + sleep onset? . Sleep midpoint has been
found to be the most reliable indicator of melatonin onset
in young healthy participants [26] with data showing mod-
erate to high correlations with Dim Light Melatonin Onset
[27]. Thus, sleep midpoint is a useful proxy marker for
circadian phase when actigraphy and sleep diaries are
utilised.
Proton magnetic resonance spectroscopy
As described elsewhere [17,28], imaging took place on a
3-Tesla GE Discovery MR750 scanner (GE Medical Sys-
tems, Milwaukee, WI) using an 8-channel phased array
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Three-dimensional sagittal whole-brain scout for orienta-
tion and positioning of subsequent scans; (b) T1-weighted
magnetization prepared rapid gradient-echo sequence pro-
ducing 196 sagittal slices to aid in the anatomical localisa-
tion of sampled voxels; and, (c) Single voxel 1H-MRS using
Point RESolved Spectroscopy (PRESS) acquisition, with two
chemical shift-selective imaging pulses for water suppres-
sion. Spectra were shimmed to achieve full-width half max-
imum of less than 13Hz. For each participant, a spectra was
acquired from a voxel measuring 20?20?20 mm placed
midline in the ACC (Figure 1; TE = 35 ms, TR = 2000 ms
and 128 averages).
Following MRS acquisition, data was transferred off-
line for post processing using the LCModel software
package [29] and metabolite concentrations were deter-
mined as a relative ratio to Creatine (Cr). All spectra
were quantified using a PRESS TE = 35 basis set of 15
metabolites. Neurometabolites of interest were NAA,
GSH and Glx. The spectra were visually inspected separ-
ately by two different raters (SD, JL) to ensure consistent
spectra and poorly fitted metabolite peaks (as reflected
by large Cramer ? Rao lower bounds greater than 20%)
were excluded from further analysis.Statistical analysis
Data were analysed using the Statistical Package for the
Social Sciences (version 20 for Mac). Student ? s t-tests
were used to compare group (unipolar vs. bipolar) data.
Pearson ? s or Spearman ? s correlations were used for con-
tinuous data as appropriate. Analyses were two tailed
and used an alpha level of 0.05.Figure 1 Example anterior cingulate cortex voxel placement and result
participant. The spectra also shows Glutathione, Glutamate + Glutamine and
NAA=N-Acetyl Aspartate; Glx = Glutamate + Glutamine.Results
Table 1 shows descriptive demographic, clinical, actigraphy
and neurometabolite data for the sample. On average, the
sample was 22 years of age with mild depressive symptoms.
The mean sleep midpoint occurred at 4:14 am but ranged
from 1:54 am to 7:05 am (median = 4:08 am). There were
no differences between unipolar and bipolar participants
in terms of age (t = −0.29, p = 0.771), gender, (x2 = 1.52,
p= 0.217) depressive symptoms (HAM-D, t = 0.86, p =
0.395), neurometabolite concentrations (Glx, t = 0.14, p =
0.173; GSH, t = 1.15, p = 0.255; NAA, t = −0.26, p = 0.797)
or sleep midpoint (t = 1.1, p = 0.915). As expected, YMRS
total score was significantly higher in bipolar participants
(t = −2.2, p = 0.034). Importantly, there were also no sig-
nificant differences between patients taking mood stabilis-
ing or antidepressant medication compared to those not
taking medication at the time of assessment in terms of
age, gender, depressive symptoms, mania symptoms, neu-
rometabolite concentrations (Glx, GSH, NAA) or sleep
midpoint (all p > 0.05).
The mean time of MRS collection was 3:42 pm (sd =
1.8 hrs). Correlations between 1H-MRS neurometabolites
and sleep midpoint showed that neither NAA or GSH
were associated with sleep midpoint (r = 0.032, p = 0.825;
r = 0.211, p = 0.151 respectively). However, as shown in
Figure 2, higher levels of ACC Glx were associated with
later sleep midpoints (rho = 0.35, p = 0.013). In order to
examine whether this association was confounded by
changes in the neurobiological and/or circadian system
due to the developmental process or to depressive state
phenomena, we conducted further analyses controlling
for age and HAM-D score. The resultant significant
partial correlations showed this relationship was robusting proton magnetic resonance spectroscopy spectra for one
N-Acetyl Aspartate peaks. Abbreviations are as follows: GSH = Glutathione;
Table 1 Demographic, clinical, actigraphic and MRS
characteristics of participants (n = 53)
Characteristic Mean ? SD
Gender, % female 71.7 (38/53)#
Age, years 21.8 ? 4.3
Hamilton depression rating scale 13.3 ? 7.0
Young Mania Rating Scalea 3.6 ? 5.3
Actigraphy
Sleep onset, time 23:50 ? 1:12
Sleep offset, time 08:37 ? 1:18
Total sleep time, hours 7:28 ? 0:30
Wake after sleep onset, mins 78.5 ? 25.6
Sleep efficiency, % 85.2 ? 4.2
Sleep midpoint, time 04:14 ? 1:09
Anterior Cingulate neurometabolites
N-Acetyl Aspartate (NAA)/Creatine 1.29 ? 0.13
Glutathione (GSH)/Creatine 0.45 ? 0.12
Glutamate/Glutamine (Glx)/Creatine 2.07 ? 0.32
#Data represents percentage and number.
aAvailable in a subset of 39 participants.
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However, when examining the relationship between ACC
Glx and sleep midpoint controlling for symptoms of
mania (i.e. YMRS scores, n = 39), the resulting partial cor-
relation was not significant (partial r = 0.06, p = 0.730).
This is despite the fact that YMRS scores alone were not
associated with ACC Glx (r = −0.29, p = 0.862). Thus,
these latter findings may be reflective of the smaller
sample with YMRS scores or alternatively may suggest
that manic symptoms mediate the relationship between
elevated ACC Glx and later sleep midpoint.Figure 2 Scatterplot showing the correlation between anterior cingul
affective disorders. Abbreviations are as follows: Glx = Glutamate + GlutamFor descriptive purposes, we secondarily examined the
association between Glx and key sleep parameters. While
the association with TST, TiB and sleep onset were not
significant (r = −0.03, p = 0.812; r = 0.10, p = 0.457; and r =
0.24, p = 0.083 respectively), Glx was significantly associ-
ated with sleep offset (r = 0.30, p = 0.030), WASO (r =
0.325, p = 0.017), and sleep efficiency (r = −0.31, p = 0.023).
Discussion
This study is the first to demonstrate an association be-
tween in vivo neurobiological measures of brain neuro-
metabolites and delayed sleep phase in young persons
with affective disorders. Specifically, higher levels of
ACC Glx, a surrogate marker of the glutamatergic sys-
tem, were associated with a later sleep midpoint, sug-
gestive of delayed circadian phase. Markers of neuronal
integrity and oxidative stress were not associated with
circadian phase in this sample.
In this study of youth with emerging affective disor-
ders, we did not find any group differences in neurome-
tabolites or sleep variables between those participants
considered by the psychiatrist to have either a unipolar
or bipolar illness. While the reasons for this are unclear,
it is possible that they reflect the fact that the symptom
severity of this sample was rather mild and encompassed
those with emerging rather than full-threshold illnesses.
That is, even those that were considered to have a ? uni-
polar ? illness may eventually progress to bipolar disorder
with longitudinal follow-up. Certainly, our data in the
sub-sample of 39 participants with detailed measure-
ment of symptoms of mania suggests that manic symp-
toms may contribute to the association between delayed
circadian phase and Glx. Thus, it is possible that those
on a trajectory to bipolar disorder are accounting for theate Glx/Cr ratio and sleep midpoint in young persons with
ine; Cr = Creatine.
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on the specificity of these findings within the affective
disorder sub-types is warranted.
These findings focussing on neurometabolites within
the ACC are aligned with those implicating the ACC in
the neurobiology of depression [30]. The ACC is densely
interconnected with the hippocampus, dorsolateral pre-
frontal cortex, amygdala, orbitofrontal cortex and hypo-
thalamus and therefore these findings may also reflect
the involvement of broader neuronal circuitry. Prior
work has shown this structure to be linked to cognitive
impairment and other phenotypic features in affective
disorders [17,31]. However, this study is the first to show
that neurometabolite concentrations within the ACC are
also relevant to sleep-wake functions. While the primary
objective of this study was to examine circadian rhythm,
secondary analyses also showed that higher levels of
ACC Glx were related to nocturnal wakefulness and
poorer sleep efficiency. Unfortunately, even in healthy
samples, little is known about the inter-relationships be-
tween ACC, mood and sleep-wake functions. However,
recent data from functional imaging studies show that
there are diurnal changes in regional cerebral blood flow
within the ACC [32], with the ACC showing a strong
circadian bias in the morning. Additionally, this region
is consistently implicated in insomnia (see review by
Speigelhalder [33]). Further studies are now needed to
further explicate how changes within the ACC circuitry
may relate to circadian misalignment and nocturnal
wakefulness in affective disorders.
While there is currently a dearth of studies that have
examined the association between circadian and spectro-
scopic markers in depressive disorders, the findings of
this study suggest that the glutamatergic system may be
implicated in the pathogenesis of this phenotypic fea-
ture. There are certainly documented dense glutamater-
gic projections from the suprachiasmatic nucleus (SCN),
via the ventral subparaventricular zone and dorsomedial
hypothalamic nucleus, to the sleep-wake centers of the
lateral hypothalamus, thereby regulating sleep-wake tim-
ing [34]. Glutamate is also a neurotransmitter of the
optic nerve and retinohypothalamic tract that the SCN
is sensitive to and this neurotransmitter does appear to
phase shift circadian rhythms [35,36].
With regard to the sleep system more generally, two
studies have shown changes in Glx in association with
sleep interventions. Specifically, Benedetti et al. [37] re-
ported that levels of ACC Glx decrease in association
with sleep deprivation, and light therapy was associated
with improvements in depressive symptoms. Accord-
ingly, Murck et al. [38] found that for males with depres-
sion, sleep deprivation is associated with an increase in
Glx. The specific role that Glx substituents assume in
sleep-wake cycles is currently unknown. However, it isclear that glutamate signalling is critically involved in
information transmission, plasticity and neurotoxicity.
Animal studies show that it increases during both waking
and rapid eye movement sleep states and when the sleep
period is preceded by wake states [39,40]. Additionally, the
rate of glutamate decrease is greatest with sleepiness and
when slow wave activity is high [39]. Thus, it is feasible
that sleep-wake history mediates glutamatergic signalling
in affective disorders, though such causative relationships
are yet to be demonstrated in humans.
While this study represents the first to examine the asso-
ciation between delayed circadian rhythms and underlying
neurobiology in youth depression, several methodological
factors should be considered when interpreting our find-
ings. Firstly, the lack of a control group is a limitation of
this study. This would have been particularly helpful for
interpretation of these findings since it is currently unclear
how sleep midpoint relates to ACC Glx in healthy adoles-
cent or even adult samples. Secondly, adolescence itself is
known to be associated with circadian delay [41]. Thus,
from these results, we cannot ascertain whether our find-
ings are reflective of adolescence generally or whether they
are specific to affective disorders. Third, although the
sample size of 53 is not particularly small for these types
of detailed neurobiological studies, this sample is rather
heterogeneous since ultimate illness trajectory is unknown
in these early clinical stages [42]. Also, a larger sample
would have been optimal in terms of conducting multi-
variable analyses whereby the influence of potential con-
founds could be determined concurrently. In terms of
other sample characteristics, it is also important to note
that details regarding female study participants? menstrual
cycle phase were not collected. Increasing evidence sug-
gests that menstrual phase affects sleep in females [36].
However we were unable to account for the possible influ-
ence of this factor. Another consideration that could have
certainly influenced circadian rhythm is psychotropic
medication [43] and larger datasets would be required to
analyse the contribution of antidepressant, mood stabilis-
ing or anti-psychotic medication.
Regarding the spectroscopy component of the study, it is
important to note that since we examined Glx as a surro-
gate marker of glutamate, the current findings may in part
be reflective of glutamine. Further research examining the
roles of Glu and glutamine are now required to further de-
lineate their role in sleep-wake function in both healthy
and psychiatric samples. Furthermore, this study used a
PRESS sequence to examine GSH concentration. Although
we have previously validated the GSH signal measured
using this sequence, replication of null findings using
MEGA-PRESS may be warranted. In this study, MRS mea-
sures were derived across various times of the day, and if
in-vivo measures of brain neurometabolites also vary ac-
cording to circadian rhythm, this is a potential source of
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a fixed time period. Finally, due to the inability to conduct
spectroscopy within the SCN or its neighbouring hypo-
thalamic sleep-wake centres, we were of course unable to
measure Glx within these regions. Thus, we cannot be
confident that ACC Glx sufficiently captures glutamatergic
concentration within regions critical for the circadian
regulation of sleep.
In terms of sleep and circadian assessment, this study
used actigraphy to derive sleep midpoint, but polysom-
nography studies may yield a more accurate determin-
ation of this measure and future investigations should
incorporate melatonin and other endogenous circadian
markers.
Conclusions
Overall, this study is the first to demonstrate a link be-
tween markers of the glutamatergic system in affective
disorders and delayed sleep-wake cycle. It enhances our
prior work examining delayed sleep and melatonin in
affective disorders [4,13,14] by specifically linking this
key phenotypic feature to a neurobiological marker im-
plicated in affective disorders, and provides an impetus
for further exploratory work in this area. Our results fur-
ther suggest that this association might be particularly
influenced by symptoms of mania. While not the focus
of this study, we also found that ACC Glx was associated
with poorer sleep, as evidenced by more nocturnal awak-
enings and poorer sleep efficiency.
Whilst these findings are preliminary and require rep-
lication in larger samples, they have potential signifi-
cance for the clinical management of young people with
emerging affective disorders. In particular, given the in-
creasing recognition of the role of glutamate in affective
disorders, it is possible that glutamatergic modulators
might help to restore circadian misalignment, which in
turn, could prevent affective symptom onset, severity
and recurrence [15].
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